FIRAZYR is indicated for the treatment of acute attacks of hereditary angioedema (HAE) in adults 18 years of age and older.

Hereditary angioedema (HAE) is a rare, debilitating, and life-threatening genetic disease characterized by recurrent attacks of angioedema without urticaria or pruritus.1,2 Acute attacks of HAE can often occur without warning.3


HAE has a global estimated prevalence ranging from 1 in 10,000 to 1 in 50,000 cases.3

Most patients start to experience attacks during childhood or adolescence and have subsequent attacks throughout their lives.2,4

The severity and frequency of HAE attacks vary greatly from patient to patient and can also change over time.2,5

Genetic basis of HAE

HAE is an autosomal dominant disorder.2 Most patients with HAE have an underlying deficiency of functional C1 esterase inhibitor that leads to excess bradykinin production.5,6

Approximately 75% of patients with HAE inherited the disease, and 25% of patients have a spontaneous genetic mutation that causes HAE.8

Most people with HAE have either type I or type II HAE.2

  • Type I is the most common form of HAE, comprising up to 85% of the HAE patient population and characterized by low levels of functional antigenic C1 esterase inhibitor.2
  • Type II, which affects the remaining 15% of patients, is characterized by normal antigenic and low functional levels of C1 esterase inhibitor.2